Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Mitsubishi_Pharma_Corporation
|
| gptkbp:areaServed |
global
|
| gptkbp:awards |
various industry awards
|
| gptkbp:clinicalTrials |
ongoing
collaborative studies Phase III trials Phase I trials Phase II trials |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:corporateSocialResponsibility |
research funding
disaster relief efforts education programs healthcare_access_initiatives |
| gptkbp:employees |
over 5,000
|
| gptkbp:focus |
research and development
|
| gptkbp:founded |
1925
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tanabe Seiyaku
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:investmentFocus |
biotechnology
medical devices healthcare_services |
| gptkbp:keyPeople |
gptkb:Yoshihiro_Matsumoto
|
| gptkbp:market |
gptkb:Asia
gptkb:Latin_America gptkb:North_America Europe |
| gptkbp:parentCompany |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| gptkbp:partnerships |
various global pharmaceutical companies
|
| gptkbp:patentCitation |
numerous pharmaceutical patents
|
| gptkbp:productLine |
prescription drugs
vaccines biologics over-the-counter products |
| gptkbp:products |
medications
|
| gptkbp:rank |
top 50 pharmaceutical companies
|
| gptkbp:regulatoryCompliance |
multiple countries
|
| gptkbp:research_areas |
diabetes
autoimmune diseases pain management gastroenterology |
| gptkbp:researchAreas |
neurology
oncology infectious diseases cardiovascular |
| gptkbp:researchInterest |
affiliated research centers
|
| gptkbp:revenue |
¥200 billion (approx.)
|
| gptkbp:subsidiary |
Tanabe Seiyaku USA, Inc.
|
| gptkbp:sustainabilityInitiatives |
community engagement
ethical practices environmental responsibility |
| gptkbp:website |
www.tanabe.co.jp
|